Jinling Pharmaceutical announced that its branch, Fuzhou Meifeng Pharmaceutical Factory, recently received the “Notice of Acceptance” from the State Drug Administration. The registration and marketing license application for carboxymaltose-iron injection drugs was accepted. The acceptance numbers are CYHS2601839 and CYHS2601840, and the specifications are 2ml: 0.1g and 10ml: 0.5g. This drug is a third-generation intravenous iron agent. Currently, only original imported products are on the market in China, and no generic drugs have been approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.